Developer docs
API playgroundTry for free, no card

Search company profiles

Nanomi

Full company profile

uuid00039rm

Namestring
Nanomi
Legal namestring
Nanomi B.V.
Websiteurl
nanomi.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Nanomi B.V. is a Dutch pharmaceutical technology company headquartered in Oldenzaal, Netherlands, operating as a wholly owned subsidiary of Indian pharmaceutical group Lupin Limited since 2014. The company develops and manufactures microsphere and nanoparticle-based long-acting release injectable medicines, built around its proprietary PrecisionSphere™ particle control technology platform (patent-protected until 2038). PrecisionSphere delivers uniform particle size, shape, and biological properties, enabling consistent drug release over treatment durations ranging from weeks to months and improved injectability via smaller-gauge needles. The company's first commercial product, Risperidone Long-Acting Injectable, received U.S. FDA approval in September 2025 with 180-day Competitive Generic Therapy exclusivity and was launched in three dosage strengths (25 mg, 37.5 mg, 50 mg) targeting a combined USD 187 million U.S. market opportunity.

Nanomi operates a B2B platform-plus-products business model with three revenue streams: technology licensing and co-development of the PrecisionSphere platform with pharmaceutical and biotech partners; contract manufacturing and R&D services for complex injectable programs including formulation development, scale-up, and technology transfer; and proprietary product development, exemplified by the Risperidone launch. Primary customers are mid-size and big pharma companies developing parenteral or long-acting injectable assets, with biotechnology companies as a secondary segment. Pricing is not publicly disclosed and is quote-based. In 2026, Nanomi completed two strategic acquisitions: VISUfarma B.V. (a European ophthalmology company with 60+ branded products and EUR 48 million in 2024 revenue) effective April 1, 2026, and a controlling stake in Multicare Pharmaceuticals Philippines for up to USD 39.6 million. These acquisitions expand Nanomi's geographic footprint across five European countries and into Southeast Asia, and add a complementary ophthalmology therapeutic vertical alongside its core long-acting injectable platform.

The company employs approximately 50 people and operates from state-of-the-art formulation, process, and analytical chemistry laboratories under EU GMP Annex 1 and GMP compliance. Recent recognitions include a 2025 CMO Award for Life Science Leadership in Drug Delivery from Lupin and Great Place To Work certification. The business is positioned as Lupin's center of excellence for complex injectable long-acting release medicines, with a strategic partnership program actively pursuing external licensing of the PrecisionSphere platform to third-party pharma companies.

Short descriptiontext

Nanomi B.V. is a Dutch pharmaceutical technology subsidiary of Lupin Limited that develops microsphere and nanoparticle long-acting injectables using its proprietary PrecisionSphere platform, serving mid-size and big pharma partners via licensing, co-development, and contract manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOldenzaal, Netherlands
HQ citystring
Oldenzaal
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
long-acting injectables, pharmaceutical manufacturing, microsphere technology, drug delivery platforms, particle engineering
Industry2 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Long-Acting Injectable Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing and Co-development
TypeLicensing Royalties
Description

Nanomi generates revenue through licensing its PrecisionSphere technology to pharmaceutical partners for development of long-acting injectable products. Offers flexible partnership models from co-development to full licensing.

nanomi.com
2Contract Manufacturing Services
TypeProfessional Services
Description

Provides custom pharmaceutical manufacturing services and R&D services to pharma and biotech partners seeking expert input for feasibility decisions, complex injectable programs, and scale-up to commercial production.

nanomi.com
3Product Development
TypeOne Time License
Description

Develops proprietary pipeline of long-acting injectable products, with first product Risperidone receiving USFDA approval. Combined estimated US sales for dosage strengths stand at USD 187 million.

lupin.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nanomi develops and manufactures microsphere and nanoparticle-based long-acting release injectable medicines using its proprietary PrecisionSphere™ particle control technology, which delivers uniform particle size, shape, and biological properties enabling consistent controlled drug release over weeks to months. The company operates as a B2B pharmaceutical technology partner, offering technology licensing, co-development, and contract manufacturing services to pharma and biotech firms, alongside its own proprietary product pipeline led by Risperidone Long-Acting Injectable commercialized through parent Lupin.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • FDA approval achieved for Risperidone long-acting injectable with 180-day CGT exclusivity, demonstrating platform validation
+1 more record
Product overview1 text field

Nanomi operates as a pharmaceutical technology company with a platform-plus-products model. Its core offering is the PrecisionSphere™ proprietary technology platform for developing long-acting release injectable medicines with uniform particle characteristics. The company's first commercial product utilizing this platform is Risperidone Long-Acting Injectable, launched in November 2025. Additionally, Nanomi (as a Lupin subsidiary) acquired VISUfarma, adding a portfolio of 60+ branded ophthalmology products across European markets. Nanomi develops microsphere and nanoparticle-based long-acting release injectables, positioning itself as a CDMO partner while building its own product pipeline.

Product and service3 records
1PrecisionSphere™ Technology Platform
CategoryPharmaceutical Technology Platform
Description

Proprietary particle control technology platform for developing long-acting release injectable medicines with uniform particle size, shape, and biological properties. Enables consistent drug release over treatment durations ranging from weeks to months and improved injectability with smaller needles. Sold through technology licensing and co-development partnerships to pharmaceutical and biotechnology companies.

2Risperidone Long-Acting Injectable
CategoryLong-Acting Injectable Pharmaceutical Product
Description

Extended-release injectable suspension for treating schizophrenia and bipolar I disorder in adults, available in three dosage strengths (25 mg, 37.5 mg, 50 mg single-dose vials). First commercial product utilizing the PrecisionSphere™ platform, bioequivalent to Risperdal Consta®. Combined estimated U.S. sales for the three dosage strengths stand at USD 187 million (IQVIA MAT September 2025). Commercialized by Lupin following FDA approval.

3Contract Manufacturing and R&D Services
CategoryContract Development and Manufacturing Services
Description

Custom pharmaceutical manufacturing and R&D services for pharma and biotech companies seeking expert input for feasibility decisions, complex injectable programs, and scale-up to commercial production. Includes technology transfer, scale-up support, and subject matter expertise for aseptic processing and sterile manufacturing.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-02
Description

Nanomi B.V., a wholly owned subsidiary of Lupin, acquired 43.38% stake in Multicare Pharmaceuticals Philippines from existing shareholders for up to $39.6 million. Acquisition expected to close by end of May 2026. Nanomi's stake was previously increased from 51% to 56.28% after MPPI buyback of shares.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

Lupin, through its wholly owned subsidiary Nanomi B.V., acquired VISUfarma B.V. from GHO Capital Partners. VISUfarma is a European ophthalmology pharmaceutical company with over 60 branded products and operations across Italy, UK, Spain, Germany, and France. VISUfarma generated €48 million in revenue in 2024. Transaction closed effective April 1, 2026.

3Contract Manufacturing Organizations (CMOs)
Strategic tierCoreTypeOthers
Description

Nanomi collaborates with CMOs and GMP-manufacturing sites for technology transfer, scale-up, and resolving technical challenges. Serves as subject matter expert for aseptic processing and sterile manufacturing.

nanomi.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Aenova is a European-headquartered CDMO with strengths in sterile liquid and lyophilized parenterals and aseptic fill-finish capacity, serving the same EU and global specialty pharma clients that Nanomi targets; it competes for LAI contract manufacturing and technology-transfer engagements in the EU market.

TypeBroad incumbent
Description

West Pharmaceutical Services supplies elastomeric components, containment systems, and integrated delivery platforms for injectables and is increasingly positioned as a partner in long-acting injectable device and formulation ecosystems; its role as an enabling supplier to LAI programs overlaps Nanomi's stakeholder map, including shared customers developing LAI products.

TypeDirect peer
Description

Evonik's Health Care division markets RESOMER biodegradable polymers and provides CDMO services for long-acting injectables and parenteral drug products, with an EU-based particle engineering footprint that directly mirrors Nanomi's PrecisionSphere microsphere/nanoparticle platform; competes for the same partnership and licensing clients targeting complex injectables.

TypeEmerging player
Description

Dalton Pharma Services is a Toronto-based specialty CDMO providing formulation, sterile fill-finish, and analytical services for complex injectables and small-molecule drug products; its scale and service mix (microbiology, GMP manufacturing, analytical) directly parallel Nanomi's three-lab CDMO offering, making it a relevant emerging peer for LAI feasibility and scale-up work.

TypeDirect peer
Description

Tolmar is a specialty pharmaceutical company that develops and manufactures long-acting injectable polymer-based products (notably Eligard for prostate cancer using in-situ gel technology); it competes head-to-head with Nanomi in the LAI oncology and endocrine space and shares the model of proprietary long-acting injectable products plus licensing/CMO services.

TypeBroad incumbent
Description

Lonza is one of the world's largest pharmaceutical CDMOs with full mammalian and parenteral capabilities, including increasingly aggressive expansion into complex injectables and LAI formulations through recent capacity investments; its scale and aseptic manufacturing depth make it the dominant broad incumbent competitor to specialty CDMOs like Nanomi.

TypeBroad incumbent
Description

Catalent (now part of Novo Holdings) operates one of the largest injectable drug product CDMO networks globally, including softgel and parenteral capabilities with significant overlap in LAI formulation and aseptic fill-finish; it is the most direct competitor to Nanomi's contract manufacturing and licensing services for parenteral long-acting injectables.

TypeDirect peer
Description

Bora Pharmaceuticals operates injectables-focused CDMO and specialty manufacturing services including sterile injectables, ophthalmics, and complex dosage forms through acquisitions in Europe and the U.S.; its injectable CDMO footprint and recent expansion overlap Nanomi's region and customer profile, making it a relevant comparably scaled CDMO peer.

TypeDirect peer
Description

Ascendia is a specialty CDMO focused on complex parenteral formulations including nanoemulsions, liposomes, and microsphere-based injectables for poorly soluble or long-acting compounds; its formulation and analytical depth aligns precisely with Nanomi's PrecisionSphere-enabled services and customer base (small and mid-size pharma developing specialty injectables).

TypeDirect peer
Description

Alkermes is the dominant independent player in long-acting injectable microsphere technology for CNS, with marketed products like Aristada (aripiprazole LAI) and Vivitrol (naltrexone LAI) and a native polymer-microsphere platform directly analogous to PrecisionSphere, making it the closest competitor and the benchmark Nanomi must beat in the LAI CNS market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nanomi

Long-Acting Injectable Pharmaceuticalsnanomi.com

Nanomi B.V. is a Dutch pharmaceutical technology subsidiary of Lupin Limited that develops microsphere and nanoparticle long-acting injectables using its proprietary PrecisionSphere platform, serving mid-size and big pharma partners via licensing, co-development, and contract manufacturing.

What Nanomi does

Nanomi B.V. is a Dutch pharmaceutical technology company headquartered in Oldenzaal, Netherlands, operating as a wholly owned subsidiary of Indian pharmaceutical group Lupin Limited since 2014. The company develops and manufactures microsphere and nanoparticle-based long-acting release injectable medicines, built around its proprietary PrecisionSphere™ particle control technology platform (patent-protected until 2038). PrecisionSphere delivers uniform particle size, shape, and biological properties, enabling consistent drug release over treatment durations ranging from weeks to months and improved injectability via smaller-gauge needles. The company's first commercial product, Risperidone Long-Acting Injectable, received U.S. FDA approval in September 2025 with 180-day Competitive Generic Therapy exclusivity and was launched in three dosage strengths (25 mg, 37.5 mg, 50 mg) targeting a combined USD 187 million U.S. market opportunity.

Nanomi operates a B2B platform-plus-products business model with three revenue streams: technology licensing and co-development of the PrecisionSphere platform with pharmaceutical and biotech partners; contract manufacturing and R&D services for complex injectable programs including formulation development, scale-up, and technology transfer; and proprietary product development, exemplified by the Risperidone launch. Primary customers are mid-size and big pharma companies developing parenteral or long-acting injectable assets, with biotechnology companies as a secondary segment. Pricing is not publicly disclosed and is quote-based. In 2026, Nanomi completed two strategic acquisitions: VISUfarma B.V. (a European ophthalmology company with 60+ branded products and EUR 48 million in 2024 revenue) effective April 1, 2026, and a controlling stake in Multicare Pharmaceuticals Philippines for up to USD 39.6 million. These acquisitions expand Nanomi's geographic footprint across five European countries and into Southeast Asia, and add a complementary ophthalmology therapeutic vertical alongside its core long-acting injectable platform.

The company employs approximately 50 people and operates from state-of-the-art formulation, process, and analytical chemistry laboratories under EU GMP Annex 1 and GMP compliance. Recent recognitions include a 2025 CMO Award for Life Science Leadership in Drug Delivery from Lupin and Great Place To Work certification. The business is positioned as Lupin's center of excellence for complex injectable long-acting release medicines, with a strategic partnership program actively pursuing external licensing of the PrecisionSphere platform to third-party pharma companies.

Nanomi firmographics

Firmographics
Name
Nanomi
Legal name
Nanomi B.V.
Website
https://nanomi.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Nanomi B.V. is a Dutch pharmaceutical technology subsidiary of Lupin Limited that develops microsphere and nanoparticle long-acting injectables using its proprietary PrecisionSphere platform, serving mid-size and big pharma partners via licensing, co-development, and contract manufacturing.
Ownership category
akta.pro rank

Nanomi industry classification

Industry
Product category
Long-Acting Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Long-acting injectables
  • Pharmaceutical manufacturing
  • Microsphere technology
  • Drug delivery platforms
  • Particle engineering

Where Nanomi is headquartered

Location

Headquarters

HQ city
Oldenzaal
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Nanomi business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Technology Licensing and Co-development: Nanomi generates revenue through licensing its PrecisionSphere technology to pharmaceutical partners for development of long-acting injectable products. Offers flexible partnership models from co-development to full licensing.
  2. Contract Manufacturing Services: Provides custom pharmaceutical manufacturing services and R&D services to pharma and biotech partners seeking expert input for feasibility decisions, complex injectable programs, and scale-up to commercial production.
  3. Product Development: Develops proprietary pipeline of long-acting injectable products, with first product Risperidone receiving USFDA approval. Combined estimated US sales for dosage strengths stand at USD 187 million.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Nanomi product offering

Product offering

Core offering

Nanomi develops and manufactures microsphere and nanoparticle-based long-acting release injectable medicines using its proprietary PrecisionSphere™ particle control technology, which delivers uniform particle size, shape, and biological properties enabling consistent controlled drug release over weeks to months. The company operates as a B2B pharmaceutical technology partner, offering technology licensing, co-development, and contract manufacturing services to pharma and biotech firms, alongside its own proprietary product pipeline led by Risperidone Long-Acting Injectable commercialized through parent Lupin.

Product overview

Nanomi operates as a pharmaceutical technology company with a platform-plus-products model. Its core offering is the PrecisionSphere™ proprietary technology platform for developing long-acting release injectable medicines with uniform particle characteristics. The company's first commercial product utilizing this platform is Risperidone Long-Acting Injectable, launched in November 2025. Additionally, Nanomi (as a Lupin subsidiary) acquired VISUfarma, adding a portfolio of 60+ branded ophthalmology products across European markets. Nanomi develops microsphere and nanoparticle-based long-acting release injectables, positioning itself as a CDMO partner while building its own product pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • PrecisionSphere™ Technology Platform Proprietary particle control technology platform for developing long-acting release injectable medicines with uniform particle size, shape, and biological properties. Enables consistent drug release over treatment durations ranging from weeks to months and improved injectability with smaller needles. Sold through technology licensing and co-development partnerships to pharmaceutical and biotechnology companies.
  • Risperidone Long-Acting Injectable Extended-release injectable suspension for treating schizophrenia and bipolar I disorder in adults, available in three dosage strengths (25 mg, 37.5 mg, 50 mg single-dose vials). First commercial product utilizing the PrecisionSphere™ platform, bioequivalent to Risperdal Consta®. Combined estimated U.S. sales for the three dosage strengths stand at USD 187 million (IQVIA MAT September 2025). Commercialized by Lupin following FDA approval.
  • Contract Manufacturing and R&D Services Custom pharmaceutical manufacturing and R&D services for pharma and biotech companies seeking expert input for feasibility decisions, complex injectable programs, and scale-up to commercial production. Includes technology transfer, scale-up support, and subject matter expertise for aseptic processing and sterile manufacturing.

Quantifiable outcome

  • FDA approval achieved for Risperidone long-acting injectable with 180-day CGT exclusivity, demonstrating platform validation
  • +1 more outcomes

Companies that use Nanomi

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Nanomi technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Nanomi partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Multicare Pharmaceuticals Philippines (MPPI)coreStrategic or Co-development Partner · 2 April 2026Nanomi B.V., a wholly owned subsidiary of Lupin, acquired 43.38% stake in Multicare Pharmaceuticals Philippines from existing shareholders for up to $39.6 million. Acquisition expected to close by end of May 2026. Nanomi's stake was previously increased from 51% to 56.28% after MPPI buyback of shares.
  • VISUfarma B.V.coreStrategic or Co-development Partner · 29 September 2025Lupin, through its wholly owned subsidiary Nanomi B.V., acquired VISUfarma B.V. from GHO Capital Partners. VISUfarma is a European ophthalmology pharmaceutical company with over 60 branded products and operations across Italy, UK, Spain, Germany, and France. VISUfarma generated €48 million in revenue in 2024. Transaction closed effective April 1, 2026.
  • Contract Manufacturing Organizations (CMOs)coreOthersNanomi collaborates with CMOs and GMP-manufacturing sites for technology transfer, scale-up, and resolving technical challenges. Serves as subject matter expert for aseptic processing and sterile manufacturing.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Nanomi competitors and assessment

Company assessment

Regional players

  • Aenova Group: Aenova is a European-headquartered CDMO with strengths in sterile liquid and lyophilized parenterals and aseptic fill-finish capacity, serving the same EU and global specialty pharma clients that Nanomi targets; it competes for LAI contract manufacturing and technology-transfer engagements in the EU market.

Broad incumbents

  • West Pharmaceutical Services: West Pharmaceutical Services supplies elastomeric components, containment systems, and integrated delivery platforms for injectables and is increasingly positioned as a partner in long-acting injectable device and formulation ecosystems; its role as an enabling supplier to LAI programs overlaps Nanomi's stakeholder map, including shared customers developing LAI products.
  • Lonza: Lonza is one of the world's largest pharmaceutical CDMOs with full mammalian and parenteral capabilities, including increasingly aggressive expansion into complex injectables and LAI formulations through recent capacity investments; its scale and aseptic manufacturing depth make it the dominant broad incumbent competitor to specialty CDMOs like Nanomi.
  • Catalent: Catalent (now part of Novo Holdings) operates one of the largest injectable drug product CDMO networks globally, including softgel and parenteral capabilities with significant overlap in LAI formulation and aseptic fill-finish; it is the most direct competitor to Nanomi's contract manufacturing and licensing services for parenteral long-acting injectables.

Direct peers

  • Evonik Industries: Evonik's Health Care division markets RESOMER biodegradable polymers and provides CDMO services for long-acting injectables and parenteral drug products, with an EU-based particle engineering footprint that directly mirrors Nanomi's PrecisionSphere microsphere/nanoparticle platform; competes for the same partnership and licensing clients targeting complex injectables.
  • Tolmar Pharmaceuticals: Tolmar is a specialty pharmaceutical company that develops and manufactures long-acting injectable polymer-based products (notably Eligard for prostate cancer using in-situ gel technology); it competes head-to-head with Nanomi in the LAI oncology and endocrine space and shares the model of proprietary long-acting injectable products plus licensing/CMO services.
  • Bora Pharmaceuticals: Bora Pharmaceuticals operates injectables-focused CDMO and specialty manufacturing services including sterile injectables, ophthalmics, and complex dosage forms through acquisitions in Europe and the U.S.; its injectable CDMO footprint and recent expansion overlap Nanomi's region and customer profile, making it a relevant comparably scaled CDMO peer.
  • Ascendia Pharmaceuticals: Ascendia is a specialty CDMO focused on complex parenteral formulations including nanoemulsions, liposomes, and microsphere-based injectables for poorly soluble or long-acting compounds; its formulation and analytical depth aligns precisely with Nanomi's PrecisionSphere-enabled services and customer base (small and mid-size pharma developing specialty injectables).
  • Alkermes: Alkermes is the dominant independent player in long-acting injectable microsphere technology for CNS, with marketed products like Aristada (aripiprazole LAI) and Vivitrol (naltrexone LAI) and a native polymer-microsphere platform directly analogous to PrecisionSphere, making it the closest competitor and the benchmark Nanomi must beat in the LAI CNS market.

Emerging players

  • Dalton Pharma Services: Dalton Pharma Services is a Toronto-based specialty CDMO providing formulation, sterile fill-finish, and analytical services for complex injectables and small-molecule drug products; its scale and service mix (microbiology, GMP manufacturing, analytical) directly parallel Nanomi's three-lab CDMO offering, making it a relevant emerging peer for LAI feasibility and scale-up work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Nanomi social profiles

Digital presence

Nanomi compliance and trust

Trust signal

Compliance3 records

Nanomi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanomi leadership team

Management profile

Number of profiles

Profiles8 records

Nanomi subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Nanomi funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanomi M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanomi

What does Nanomi do?

Nanomi develops and manufactures microsphere and nanoparticle-based long-acting release injectable medicines using its proprietary PrecisionSphere™ particle control technology, which delivers uniform particle size, shape, and biological properties enabling consistent controlled drug release over weeks to months. The company operates as a B2B pharmaceutical technology partner, offering technology licensing, co-development, and contract manufacturing services to pharma and biotech firms, alongside its own proprietary product pipeline led by Risperidone Long-Acting Injectable commercialized through parent Lupin.

Is Nanomi a public or private company?

Nanomi is a private company. It is classified as corporate owned and is currently operating.

When was Nanomi founded?

Nanomi was founded in 2014. It employs 51 to 100 people.

Where is Nanomi based?

Nanomi is headquartered in Oldenzaal, Netherlands, in the Europe region.

How does Nanomi make money?

Three revenue lines are on record. Technology Licensing and Co-development is the primary driver. The others are contract Manufacturing Services and product Development.

Who are Nanomi's main competitors?

Aenova Group is listed as a regional player. Broad incumbents are West Pharmaceutical Services, Lonza and Catalent. Direct peers are Evonik Industries, Tolmar Pharmaceuticals, Bora Pharmaceuticals, Ascendia Pharmaceuticals and Alkermes. Dalton Pharma Services is listed as an emerging player.

Does Nanomi have an API?

No public API is recorded for Nanomi.

What industry is Nanomi in?

Nanomi's product category is Long-Acting Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXLupin unit Nanomi completes MPPI stake acquisitionLupin's wholly owned subsidiary Nanomi B.V. has consolidated its stake in Multicare Pharmaceuticals Philippines Inc. to 99.89% effective July 1, 2026, up from its previous 56.28% holding. The increase was achieved through the acquisition of 11,794,497 shares and the buyback of 61,118 shares, with an additional buyback of 30,559 shares currently in progress. This near-total acquisition strengthens Lupin's control over its Philippine operations and expands its footprint in the Southeast Asian pharmaceutical market.ScanXLupin Completes VISUfarma Acquisition, Expands Eye Care Portfolio to 60+ ProductsLupin Limited, through its Netherlands-based wholly owned subsidiary Nanomi B.V., completed the acquisition of VISUfarma B.V. on April 1, 2026, purchasing the entire share capital from GHO Capital Partners LLP. The transaction adds over 60 branded eye care products spanning dry eye, glaucoma, and retinal health segments, while bringing €53 million in revenue and strengthening Lupin's commercial footprint across Italy, UK, Spain, Germany, and France. The acquisition is expected to be immediately accretive and accelerate Lupin's specialty franchise build-out in Europe.PR NewswireLupin lance un programme de partenariats stratégiques pour étendre la portée de sa plateforme de produits injectables à action prolongéeLupin Limited announced the launch of a strategic partnership program to expand the reach of PrecisionSphere™, a long-acting injectable drug delivery platform developed by its subsidiary Nanomi B.V. The platform has demonstrated satisfactory efficacy and safety and received FDA approval for its first product, positioning it to help pharmaceutical companies develop extended-release injectable drugs across therapeutic areas. The program aims to collaborate with companies seeking to extend product lifecycles through long-acting formulations, leveraging Lupin's regulatory expertise and scalable manufacturing capabilities.PR NewswireLupin presenta un programa para ampliar el alcance de su plataforma inyectable de acción prolongadaLupin Limited announced the launch of a strategic partnership program to expand the reach of PrecisionSphere™, its long-acting injectable (LAI) drug delivery platform developed by subsidiary Nanomi B.V. The platform, which recently received FDA approval for its first developed product, enables pharmaceutical companies to manufacture drugs with consistent particle size, shape, and biological properties, allowing constant drug release over weeks to months. The program aims to collaborate with companies seeking to extend product lifecycles through longer-acting formulations.PR NewswireLupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable PlatformLupin Limited announced a strategic partnership program to expand the commercial reach of PrecisionSphere™, a long-acting injectable platform developed by its subsidiary Nanomi B.V., following recent U.S. FDA approval for the first product using this technology. The program targets pharmaceutical companies seeking to extend product lifecycles through longer-acting formulations, leveraging PrecisionSphere's ability to produce consistent particle size and optimized drug release ranging from weeks to months. The platform addresses compliance issues that cost pharmaceutical companies significant revenue from variable treatment outcomes.PR NewswireLupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable PlatformLupin Limited announced the launch of a strategic partnership program to expand the global reach of PrecisionSphere™, a long-acting injectable (LAI) platform developed by its subsidiary Nanomi B.V., following recent U.S. FDA approval for the first product utilizing this technology. The partnership program is designed to enable pharmaceutical companies to extend product lifecycles through longer-acting formulations, leveraging the platform's ability to manufacture medicines with consistent particle size, shape, and biological properties. Lupin stated it has proven alliance management capabilities and aims to accelerate patient access to advanced LAI treatments across various therapeutic areas.PR NewswireLupin refuerza su negocio global de oftalmología especializada con la adquisición de VISUfarma de GHO CapitalLupin Limited announced that its wholly-owned subsidiary Nanomi B.V. has signed a definitive agreement to acquire VISUfarma B.V., a portfolio company of GHO Capital Partners LLP, to strengthen its global ophthalmology specialty business. VISUfarma operates across major European markets including Italy, UK, Spain, Germany, and France with a portfolio of over 60 branded ophthalmological products and generated €48 million in revenue in 2024. The transaction, expected to close by the end of 2025 pending certain conditions, will be financed with Lupin's existing cash and is anticipated to drive growth and margin expansion while providing direct market presence in key European countries.PR NewswireLupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO CapitalLupin Limited, through its wholly owned subsidiary Nanomi B.V., has signed a definitive agreement to acquire VISUfarma B.V., a pan-European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners. The €48m revenue company brings 60+ branded ophthalmology products and established commercial operations across Italy, the UK, Spain, Germany, and France, which will expand Lupin's specialty franchise and European footprint. The transaction, expected to close by end of 2025 and financed with existing cash, is projected to be immediately accretive to Lupin's growth and margin profile.PR NewswireLupin kriegt die US-FDA-Zulassung für Risperidon als langwirksame Injektion mit 180 Tagen CGT-Exklusivität, das erste Produkt von Nanomis Plattform für langwirksame InjektionenPharmaceutical company Lupin received FDA approval for its Risperidone long-acting injectable suspension (25mg, 37.5mg, 50mg single-dose vials), marking the first product utilizing Nanomi B.V.'s proprietary technology platform and carrying 180-day CGT exclusivity. The product is bioequivalent to Johnson & Johnson's Risperdal Consta® and is indicated for schizophrenia treatment and bipolar I disorder maintenance therapy, with estimated US annual sales of $190 million (IQVIA MAT July 2025). Lupin executives cited the first-cycle approval as validation of their complex injectable development capabilities and announced plans to leverage the Nanomi platform for additional novel long-acting injectable products.PR NewswireLupin reçoit l'approbation de la FDA américaine pour la rispéridone injectable à action prolongée, avec une exclusivité CGT de 180 jours, le premier produit de la plateforme de médicaments injectablesLupin Limited received FDA approval for its abbreviated new drug application for extended-release injectable risperidone suspension (25mg, 37.5mg, and 50mg single-dose vials), the first product utilizing its Nanomi B.V. platform technology for long-acting injectables, qualifying for 180 days of Competitive Generic Therapy exclusivity. The product serves as a bioequivalent to Risperdal Consta® and is indicated for schizophrenia treatment and bipolar I disorder maintenance therapy, with estimated annual US sales of $190 million for the reference product as of July 2025. Lupin CEO Vinita Gupta and Chief Scientific Officer Dr. Shahin Fesharaki highlighted the approval as validation of the company's complex injectable capabilities and a foundation for expanding their specialized product pipeline.